Tixagevimab/AZD8895 represents a unique therapeutic strategy utilizing dual monoclonal proteins. Specifically, these medications work by selectively connecting to the spike region of the SARS-CoV-2 virus, preventing https://www.targetmol.com/compound/tixagevimab